144 related articles for article (PubMed ID: 12438953)
1. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome.
Dotti G; Fiocchi R; Motta T; Mammana C; Gotti E; Riva S; Cornelli P; Gridelli B; Viero P; Oldani E; Ferrazzi P; Remuzzi G; Barbui T; Rambaldi A
Transplantation; 2002 Oct; 74(8):1095-102. PubMed ID: 12438953
[TBL] [Abstract][Full Text] [Related]
2. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
4. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.
Leblond V; Sutton L; Dorent R; Davi F; Bitker MO; Gabarre J; Charlotte F; Ghoussoub JJ; Fourcade C; Fischer A
J Clin Oncol; 1995 Apr; 13(4):961-8. PubMed ID: 7707124
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
6. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant.
Dotti G; Fiocchi R; Motta T; Gamba A; Gotti E; Gridelli B; Borleri G; Manzoni C; Viero P; Remuzzi G; Barbui T; Rambaldi A
Transplantation; 2000 Mar; 69(5):827-33. PubMed ID: 10755535
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
[TBL] [Abstract][Full Text] [Related]
9. Thoracic presentations of posttransplant lymphoproliferative disorders.
Halkos ME; Miller JI; Mann KP; Miller DL; Gal AA
Chest; 2004 Dec; 126(6):2013-20. PubMed ID: 15596707
[TBL] [Abstract][Full Text] [Related]
10. Non-Hodgkin lymphoma after liver and kidney transplantation in children. Experience from one center.
Dembowska-Bagińska B; Wakulińska A; Daniluk I; Teisseyre J; Jankowska I; Czubkowski P; Grenda R; Jarmużek W; Grajkowska W; Małdyk J; Kaliciński P
Adv Clin Exp Med; 2020 Feb; 29(2):197-202. PubMed ID: 32154678
[TBL] [Abstract][Full Text] [Related]
11. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
[TBL] [Abstract][Full Text] [Related]
13. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.
Nalesnik MA; Jaffe R; Starzl TE; Demetris AJ; Porter K; Burnham JA; Makowka L; Ho M; Locker J
Am J Pathol; 1988 Oct; 133(1):173-92. PubMed ID: 2845789
[TBL] [Abstract][Full Text] [Related]
14. EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder?
Gibson SE; Swerdlow SH; Craig FE; Surti U; Cook JR; Nalesnik MA; Lowe C; Wood KM; Bacon CM
Am J Surg Pathol; 2011 Jun; 35(6):807-15. PubMed ID: 21552113
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
Ghobrial IM; Habermann TM; Maurer MJ; Geyer SM; Ristow KM; Larson TS; Walker RC; Ansell SM; Macon WR; Gores GG; Stegall MD; McGregor CG
J Clin Oncol; 2005 Oct; 23(30):7574-82. PubMed ID: 16186599
[TBL] [Abstract][Full Text] [Related]
16. Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes.
Berglund D; Kinch A; Edman E; Backlin C; Enblad G; Larsson E; Molin D; Pauksens K; Sundström C; Baecklund E
Transplantation; 2015 May; 99(5):1036-42. PubMed ID: 25211518
[TBL] [Abstract][Full Text] [Related]
17. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
[TBL] [Abstract][Full Text] [Related]
19. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder.
Collins MH; Montone KT; Leahey AM; Hodinka RL; Salhany KE; Belchis DA; Tomaszewski JE
Pediatrics; 2001 Jun; 107(6):E89. PubMed ID: 11389287
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
Taylor AL; Bowles KM; Callaghan CJ; Wimperis JZ; Grant JW; Marcus RE; Bradley JA
Transplantation; 2006 Aug; 82(3):375-81. PubMed ID: 16906036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]